Goldman Sachs Group Inc. Sells 28,686 Shares of Celcuity, Inc. $CELC

Goldman Sachs Group Inc. reduced its holdings in shares of Celcuity, Inc. (NASDAQ:CELC) by 24.4% in the first quarter, according to its most recent filing with the SEC. The fund owned 89,073 shares of the company’s stock after selling 28,686 shares during the period. Goldman Sachs Group Inc. owned about 0.24% of Celcuity worth $901,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. GAMMA Investing LLC increased its holdings in shares of Celcuity by 1,237.4% in the 1st quarter. GAMMA Investing LLC now owns 1,324 shares of the company’s stock valued at $131,000 after acquiring an additional 1,225 shares during the period. Focus Financial Network Inc. purchased a new position in shares of Celcuity in the 1st quarter valued at about $108,000. Perkins Capital Management Inc. purchased a new position in shares of Celcuity in the 1st quarter valued at about $115,000. Tema Etfs LLC purchased a new stake in Celcuity during the 1st quarter worth approximately $158,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Celcuity by 16.2% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 19,725 shares of the company’s stock worth $258,000 after buying an additional 2,756 shares in the last quarter. 63.33% of the stock is currently owned by hedge funds and other institutional investors.

Celcuity Price Performance

Shares of CELC opened at $52.49 on Tuesday. The company has a debt-to-equity ratio of 2.24, a quick ratio of 4.58 and a current ratio of 4.58. The company has a market capitalization of $2.23 billion, a price-to-earnings ratio of -15.21 and a beta of 0.72. Celcuity, Inc. has a fifty-two week low of $7.57 and a fifty-two week high of $63.06. The firm has a 50-day simple moving average of $43.64 and a 200-day simple moving average of $22.42.

Celcuity (NASDAQ:CELC) last announced its quarterly earnings data on Thursday, August 14th. The company reported ($1.04) EPS for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.14). On average, equities research analysts anticipate that Celcuity, Inc. will post -2.62 earnings per share for the current year.

Insider Transactions at Celcuity

In other Celcuity news, Director David Dalvey sold 100,000 shares of the stock in a transaction dated Monday, July 28th. The shares were sold at an average price of $43.98, for a total value of $4,398,000.00. Following the completion of the transaction, the director directly owned 125,000 shares of the company’s stock, valued at approximately $5,497,500. This trade represents a 44.44% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 15.78% of the company’s stock.

Wall Street Analyst Weigh In

CELC has been the topic of several recent research reports. Needham & Company LLC lowered their target price on Celcuity from $74.00 to $70.00 and set a “buy” rating on the stock in a report on Friday, August 15th. Leerink Partners upped their price target on Celcuity from $28.00 to $60.00 and gave the stock an “outperform” rating in a research note on Monday, July 28th. Stifel Nicolaus assumed coverage on Celcuity in a research note on Tuesday, July 1st. They set a “buy” rating and a $30.00 price target on the stock. Guggenheim assumed coverage on Celcuity in a research report on Monday. They set a “buy” rating on the stock. Finally, HC Wainwright upped their price objective on Celcuity from $50.00 to $66.00 and gave the stock a “buy” rating in a research report on Monday, August 18th. Five analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $56.50.

About Celcuity

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.